Direct-to-consumer genetic testing for factor V Leiden and prothrombin 20210G>A: the consumer experience.

ABSTRACT:

Background

Clinical genetic testing for inherited predisposition to venous thromboembolism (VTE) is common among patients and their families. However, there is incomplete consensus about which individuals should receive testing, and the relative risks and benefits.

Methods

We assessed outcomes of receiving direct-to-consumer (DTC) results for the two most common genetic risk factors for VTE, factor V Leiden in the F5 gene (FVL) and prothrombin 20210G>A in the F2 gene (PT). Two thousand three hundred fifty-four customers (1244 variant-positive and 1110 variant-negative individuals) of the personal genetics company 23andMe, Inc., who had received results online for F5 and F2 variants, participated in an online survey-based study. Participants responded to questions about perce

SUBMITTER: Elson SL 

PROVIDER: S-EPMC7667316 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature